ライフサイエンスコーパス: tail vein

1 HER2)-Luc human breast cancer cells into the tail vein.

2 ion, mice received 100,000 MSC or saline via tail vein.

3 203S-CypD or WT CypD into CypD(-/-) mice via tail vein.

4 ressure injection of a DNA solution into the tail vein.

5 3.7- to 7.4-MBq (18)F-FDG injection via the tail vein.

6 .0 MBq of (188)Re-(Arg(11))CCMSH through the tail vein.

7 x 14.8 MBq of (188)Re-(Arg(11))CCMSH via the tail vein.

8 construct was injected intravenously via the tail vein.

9 mice after injection of tumor cells into the tail vein.

10 l Research Institute mice inoculated via the tail vein.

11 -7.4 MBq [50-200 muCi]) was injected via the tail vein.

12 ns of fluorescent probe administered via the tail vein.

13 r (5-10 microg of protein) were injected via tail vein.

14 orescent protein (GFP)-positive BMCs via the tail vein.

15 ral blood CD34+ cells were injected into the tail vein.

16 In some rats, drugs were delivered via the tail vein.

17 lowing injection of carcinoma cells into the tail vein.

18 injected them into FIX knockout mice via the tail vein.

19 mul PBS) were injected into Balb/cj mice via tail veins.

20 uL of NETs (20 uM ICG,) was IV injected via tail vein 1-hour prior to photoacoustic (PA) and fluores

21 ceived i.v. donor C3H cell infusions via the tail vein: 1) 5.0x10(7) wild-type donor spleen cells (SP

22 chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers.

23 ce with plasma FVII < 1% of normal, a single tail vein administration of AAV (1 x 10(13) vector genom

24 ice were visualized at 4, 12, and 24 h after tail vein administration of the (99m)Tc-CCND1 antisense

25 principal organ of tracer localization after tail-vein administration of 64Cu-PTSM alone.

26 ved from long-term, low-pressure, low-volume tail-vein administrations.

27 hat systemic transplantation of SHED via the tail vein ameliorates ovariectomy (OVX)-induced osteopen

28 ndibular gland (SMG) or to the liver via the tail vein and assessed transgenic protein expression and

29 s infused at a constant rate via the lateral tail vein and clonus onset was recorded in the presence

30 S100A9 concentrations in blood are lowest in tail vein and highest in the lungs, which most likely gu

31 ld-type controls, BrdU was injected into the tail vein and labeled on en face preparation.

32 bes BMV109 and BMV101, respectively, via the tail vein and noninvasively imaged by optical and small-

33 G while higher levels were obtained from the tail vein and the SMG; however, vector particle containm

34 kBq [20 micro Ci]) was administered via the tail vein and uptake was determined in selected tissues

35 ransduced SP cells were transplanted via the tail vein and were shown to successfully deliver enhance

36 venous (1 x 10(7). per mouse via the lateral tail vein), and muscle (1 x 10(8) CFU per mouse intramus

37 Tracer was injected via the tail vein, and dynamic PET scans were acquired for 90 mi

38 dextran-fluorescein isothyocyanate into the tail vein, and half of them were exposed to high-intensi

39 ICG was injected into the mouse tail vein, and images were taken by in vivo confocal mic

40 were injected into tumor-bearing mice via a tail vein, and these lipoplexes accumulated sufficiently

41 0(6) BMSCs in PBS (n=8) were injected into a tail vein at 1 day postischemia.

42 Rats were divided into three groups: tail vein bacterial injection on day 0 (no fibrin group)

43 Anti-ADAMTS-18 Ab shortens the tail vein bleeding time.

44 Moreover, despite normal tail vein bleeding times, mKng1(-/-) mice displayed a si

45 similar activated partial thromboplastin and tail vein bleeding times.

46 gh injection of anti-TFPI antibody mitigated tail vein bleeding.

47 nt and activity in plasma, and performed the tail-vein bleeding test and the carotid artery ferric ch

48 endently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idaruciz

49 In tail vein blood collected on three separate days 60 min

50 Graft function was measured by daily tail vein blood glucose levels, with rejection defined a

51 Furthermore, tail vein delivery of purified CCN1 protein accelerates

52 yielded up to 84-fold more hFIX protein than tail vein delivery, corroborated by similarly increased

53 ts of (125)I-Ad-3Delta-A20T up to 48 h after tail vein delivery.

54 expression in the liver of mice following a tail vein dose of a polyplex, composed of 1 mug of pGL3

55 ed contrast material was infused through the tail vein for 5 minutes.

56 ivered to the liver by a single hydrodynamic tail vein (HTV) injection.

57 in which diffuse MM lesions developed after tail vein i.v. injection of human RPMI-8226/S MM cells s

58 cells (1.2 x 106) were administered through tail vein immediately after reperfusion and at 6 hrs and

59 kidneys and spleen after inoculation via the tail vein in a bacteremia mouse model.

60 luciferase (5TGM1/luc) were inoculated from tail vein in bg/xid/nd mice.

61 acute liver injury, we transplanted them via tail vein in mice injected intraperitoneally with a sing

62 Adenovirus-PPARgamma1 injected into the tail vein induced hepatic steatosis in PPARalpha(-/-) mi

63 ing the production of [3-(13)C]lactate after tail vein infusion of labeled [1-(13)C]glucose.

64 Tail vein infusion of syngeneic MSC and MSC:SDF-1 1 day

65 uptake of (89)Zr-BVDFO on carotid artery and tail vein infusion with an intact BBB or with BBB openin

66 ant pentylenetetrazol (PTZ), given via timed tail vein infusion.

67 oute of uptake with time-course MRI during a tail-vein infusion of manganese.

68 Animals received 6-hr tail vein infusions, commencing 18 hrs after cecal ligat

69 = 8) or replaced by HSV1-sr39tk (n = 18) was tail-vein injected into mice.

70 ell as in the liver and lungs of living mice tail-vein injected with coelenterazine.

71 , severe combined immunodeficiency mice were tail-vein injected with human melanoma cell lines (A375-

72 At 12weeks of age, brain uptake of tail vein-injected ((3))H-2-deoxy glucose in Glut3(+/-)

73 active and fails to trigger dissemination of tail vein-injected cells in a mouse model of metastasis.

74 etastasis of orthotopically implanted 4T1 or tail vein-injected MDA-MB-231T cells (P = 0.001 and 0.04

75 abetic and age-matched nondiabetic mice were tail vein-injected with 10(8) CFU of Klebsiella pneumoni

76 MicroPET images of living mice indicate that tail-vein-injected labeled C6 cells traffic to the lungs

77 In mice, tail-vein-injected LOXCAT lowered the circulating lactat

78 ormation and hepatosplenic infiltration in a tail-vein-injected mouse model.

79 yte number in living mice was assessed after tail vein injection (150 mug of each conjugate per mouse

80 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination.

81 of HCC tumors induced using the hydrodynamic tail vein injection and orthotopic implantation models i

82 he number of metastatic nodules in mice with tail vein injection and orthotopic implantation.

83 In the subcutaneous xenograft and tail vein injection assays, these cells had significantl

84 tumor cell extravasation into the lung after tail vein injection compared with tumors expressing wild

85 substantially inhibited lung colonization in tail vein injection experiments in immunodeficient mice.

86 ty of approximately 12 MBq (64)Cu-GPVI-Fc by tail vein injection followed by delayed (24 hours) posit

87 promoter fragments was confirmed in vivo by tail vein injection followed by luciferase reporter assa

88 ted with mismatch or H2HR vivo-morpholino by tail vein injection for 1 week.

89 by adeno-associated viral vector via single tail vein injection immediately following induction of M

90 ), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model.

91 ting capsids by direct in vivo panning after tail vein injection in mice.

92 n immunoliposomes to the mesangium following tail vein injection in mice.

93 the blood-brain barrier, to access brain via tail vein injection in mice.

94 merulus and glomerular mesangial cells after tail vein injection in normal and nephritic mice.

95 el and that DN-PPARgamma ECV304 cells, after tail vein injection in nude mice, form lumen-obliteratin

96 imental lung metastasis model established by tail vein injection in severe combined immunodeficient m

97 and metastasis in vitro and in cells before tail vein injection in vivo.

98 )-labeled Abeta42 and Abeta40 introduced via tail vein injection into mice with a BBB rendered permea

99 Following tail vein injection into rats, (M6P)(20)-BSA-(33)P-TFO r

100 ferase-positive splenocytes, transferred via tail vein injection into the brains of HSV-infected anim

101 enhancer, was delivered through hydrodynamic tail vein injection into VWF knockout mice (VWF(-/-)) th

102 mic administration of siMGMT-SNAs via single tail vein injection is capable of robust intratumoral MG

103 in vivo BALB/c nude mice xenograft model and tail vein injection model showed that berberine treatmen

104 ased replication assay with the hydrodynamic tail vein injection model to investigate the function(s)

105 with ketamine/xylazine and catheterized for tail vein injection of (11)C-raclopride.

106 RLT was performed by administering a single tail vein injection of (177)Lu-PSMA-617 at different for

107 s performed in wild-type rats at 1 hour post tail vein injection of (64)Cu-DOTA-ECL1i.

108 omized into subgroups that received either a tail vein injection of 3 x 10 orbital fat-derived stem/s

109 ution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 microCi) of the (11)

110 One and 2 h after tail vein injection of 30 x 10(6) ex vivo (18)F-FDG-labe

111 by counting tumor cells in lung at 6 h after tail vein injection of a mixture of fluorescently tagged

112 When SIRT4 was knocked down in vivo by tail vein injection of a shRNA adenovirus, we observed a

113 Tail vein injection of a standard Ad5-based vector into

114 rmed in an animal model of lung cancer using tail vein injection of A549 cells in SCID mice.

115 In adult mice, tail vein injection of AAV9-GFP leads to robust transduc

116 Tail vein injection of adenovirus expressing the HNF6 co

117 Finally, tail vein injection of an M2pep fusion peptide with a pr

118 A tail vein injection of anti-DLK1 Ab at 6 h after PH redu

119 PET data were acquired after tail vein injection of approximately 9 MBq of (18)F-FPAC

120 atic lung melanoma tumour-bearing mice after tail vein injection of both treatments, suggesting that

121 Tail vein injection of human endothelial specific Ulex e

122 lity of ultrafast multislice (13)C MRI after tail vein injection of hyperpolarized (13)C-phospholacta

123 Furthermore, tail vein injection of miR-223 lentiviral vector to miR-

124 to 4, microPET images were obtained after a tail vein injection of nitrogen-13 ammonia ([13N]-NH3) a

125 bserved in mouse CCA induced by hydrodynamic tail vein injection of notch intracellular domain (NICD)

126 Following tail vein injection of OS cells into mice, both molecule

127 etent mice with HCC, induced by hydrodynamic tail vein injection of proto-oncogenes, enhanced HCC dev

128 s of ocular and brain tissues after a single tail vein injection of SVV-001 (1 x 10(13) vp/kg) showed

129 A single tail vein injection of the rAAV8 vector was as efficient

130 njected dose per gram (%ID/g) 72 hours after tail vein injection of the radiolabeled probe in subcuta

131 the number of lung metastases 14 days after tail vein injection of tumor cells, with alveolar wall i

132 bserved in a VEGF-dependent manner following tail vein injection of tumor cells.

133 of Cre-recombinase in ILK-floxed animals by tail vein injection resulted in acute hepatitis, with a

134 earing B16/F10 and A375M tumors at 1 h after tail vein injection revealed good B16/F10 tumor-to-backg

135 er a functional human ABCC6 via hydrodynamic tail vein injection to approximately 13% of mouse hepato

136 ntibody (Ab; DOTA-30F11) was administered by tail vein injection to athymic mice bearing disseminated

137 CC, or control Cas9 vector, via hydrodynamic tail vein injection to livers of 8-week-old female FVB/N

138 was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine.

139 pecific gene transfer following hydrodynamic tail vein injection using the kidney-specific podocin an

140 Metastasis to the lung via tail vein injection was reduced in the 4T1-WNT5A express

141 es for (18)F-FPA and (14)C-acetate 1 h after tail vein injection were 7.08 +/- 0.80 and 0.36 +/- 0.08

142 he rAAV FIX genome in liver and spleen after tail vein injection with a higher proportion in liver af

143 nockout (CD18-ko) and wild-type (WT) mice by tail vein injection with Listeria.

144 ly divided to six groups and received weekly tail vein injection with PBS, EGCG, void nanoparticles (

145 Male BALB/c mice were infected via tail vein injection with wild-type C. albicans or with a

146 s of CN-105 (0.05 mg/kg) was administered by tail vein injection within 24 hours after ICH induction.

147 asis from orthotopic primaries and following tail vein injection without further VEGF treatment.

148 Following lateral tail vein injection, 3T3 cells transformed by constituti

149 he vector was administered into nude mice by tail vein injection, and exogenous creatine was administ

150 ice were infected with MUP1 adenoviruses via tail vein injection, and recombinant MUP1 was overexpres

151 Following tail vein injection, fluorescence arising from dye-conju

152 accumulation of M2pep in TAMs in vivo after tail vein injection.

153 , or phosphate buffered saline (PBS) through tail vein injection.

154 from anesthesia when administered to mice by tail vein injection.

155 pic reinjection and of lung metastases after tail vein injection.

156 showed increased pulmonary tumor growth upon tail vein injection.

157 idiasis with C. albicans A72 administered by tail vein injection.

158 ng in vivo bioluminescence imaging following tail vein injection.

159 livers of outbred ICR mice via hydrodynamic tail vein injection.

160 in the lung after systemic administration by tail vein injection.

161 . actinomycetemcomitans were transferred via tail vein injection.

162 HBV vector were codelivered via high-volume tail vein injection.

163 essed formation of lung metastases following tail vein injection.

164 ses of more aggressive carcinoma cells after tail vein injection.

165 to the livers of mice by using high-pressure tail vein injection.

166 line reduces colonization of the lungs in a tail vein injection.

167 HepG2 colonization into lung and liver after tail vein injection.

168 by administering an insulin stimulation via tail vein injection.

169 ration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

170 tively transferred to recipient mice through tail vein injection.

171 ells to colonize the lung when delivered via tail vein injection.

172 and administered to healthy mice by lateral tail vein injection.

173 ng proved fast clearance of the tracer after tail vein injection.

174 re retained in the murine lung 6 h following tail vein injection; coexpression of EDG2 enhanced reten

175 ation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models

176 nomas were treated with 10 mg/kg of 5-Se via tail-vein injection and with 720 J cm(-2) of 570-750-nm

177 In mouse tail-vein injection experiments, a construct containing

178 pharmacokinetic data equivalent to data from tail-vein injection for small-animal (18)F-FDG PET.

179 nvasion and formation of lung colonies after tail-vein injection in SCID mice.

180 as surrounding omega1-mutated eggs following tail-vein injection into mice was vastly reduced.

181 mine or polyethyleneimine alone (placebo) by tail-vein injection into nude mice with prostate and bre

182 s(-1) and arrested in the lungs 2-3 s after tail-vein injection into the mice, which is consistent w

183 In a tail-vein injection metastatic model, Frzb-transfected H

184 ost-myocardial infarction were randomized to tail-vein injection of 2x10(6) MSCs, with injection repe

185 MIR122 was inhibited in mice by tail-vein injection of an oligonucleotide antagonist of

186 Tail-vein injection of B16-F10 cells that stably express

187 tal metastasis assay we detail here includes tail-vein injection of cancer cells into the mouse and d

188 Orthotopic reinjection and tail-vein injection of cells arising from tumors, couple

189 ing, CCl4 is administered for 12 weeks after tail-vein injection of Cre-expressing adenovirus (adeno-

190 Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid deve

191 ouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine

192 cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell

193 tinal (GI) tumors in immunodeficient mice by tail-vein injection rather than surgery.

194 ransposon, delivered as naked plasmid DNA by tail-vein injection, to integrate B-domain-deleted FVIII

195 of these cells to form lung metastases after tail-vein injection, whereas mTerc reconstitution alone

196 le to form pulmonary tumor nodules following tail-vein injection.

197 cally investigated using intraperitoneal and tail-vein injection.

198 at the time of liver injury via hydrodynamic tail-vein injection.

199 d 1 hr after initiation of sepsis via single tail-vein injection.

200 ility form lung metastases in mice following tail-vein injection.

201 BL/6J mice were randomly assigned to receive tail vein injections of 1 mug/kg of remifentanil or norm

202 or TBI dose level per experiment were given tail vein injections of 100 microg of (131)I-labeled 30F

203 Some mice were given tail vein injections of a vector encoding a secreted for

204 In this study, we show that mouse tail vein injections of adenovirus expressing the rat HN

205 In tail vein injections of alternative cancer models, bicar

206 Mice were given hydrodynamic tail vein injections of clustered regularly interspaced

207 Tail vein injections of Sod2-GFP-expressing HT-1080 cell

208 ter implantation only (n = 99); 176 received tail vein injections of Staphylococcus epidermidis on po

209 the approach in mice, C57BL/6 mice received tail vein injections of two vectors, AAV8-SaCas9-gRNA, t

210 toris (phLAL), purified, and administered by tail vein injections to lal( -/-) mice.

211 ioned with carbon monoxide were delivered by tail vein injections to septic mice.

212 evels during BDL liver injury, we used mouse tail vein injections with recombinant adenovirus express

213 and lung colonization after subcutaneous and tail vein injections, respectively.

214 hydrolase (Fah) mutant mice via hydrodynamic tail vein injections.

215 e-matched, irradiated LH(BETA)T(AG) mice via tail vein injections.

216 aluated AAV8 against AAV2 in intraportal and tail vein injections.

217 ificantly larger effects in both organs than tail vein injections.

218 NS alphaS pathology in M83 mice than i.p. or tail vein injections.

219 ey rats (n = 36) were studied at 9.4 T after tail vein injections.

220 lung cancer cell dissemination in mice after tail vein injections.

221 In addition, tail-vein injections in mice with human breast cancer MC

222 ice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.

223 Mice were given 1 or 2 tail-vein injections of TIMP-GLIA or control nanoparticl

224 butions of the nanoparticles 24 h after i.v. tail-vein injections show that the nanoparticle accumula

225 By performing hydrodynamic tail-vein injections, we tested the impact of altering a

226 xpressed in the mouse liver via hydrodynamic tail-vein injections.

227 detected in both spleen and brain 3 wk after tail vein inoculation, and it induced expression of infe

228 After tail vein inoculation, most luciferase-generated biolumi

229 ng Transwells, and lung metastasis following tail vein inoculation.

230 d cause a lethal infection in mice following tail vein inoculation.

231 istration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates earl

232 uorobenzoate (2-3 MBq) were injected via the tail vein into nude mice xenografted with BxPC3 (integri

233 nsduced B16 melanoma cells were injected via tail vein into syngeneic C57BL/6 mice.

234 chieved by the parent compounds, yet free of tail vein irritation and histamine induced toxicity in v

235 munocompromised mice, and when injected into tail veins, led to lung metastasis.

236 n vitro and metastatic foci development in a tail vein lung metastasis model in mice.

237 compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells

238 nd, heterotopic murine Lewis lung cancer and tail vein metastasis tumor model systems in betaarr2-def

239 fewer pulmonary metastases than controls in tail-vein metastasis assays.

240 drochloride liposomes were injected into the tail vein: Mice received therapy with doxorubicin inject

241 prime determinant of virulence in the mouse tail vein model of candidiasis and that the attenuated v

242 inant metastatic disease in the lung using a tail vein model of haematogenous spread through accelera

243 idence of lung metastasis in vivo in a mouse tail vein model.

244 ffinity chromatography and injected into the tail vein of apolipoprotein E-deficient mice.

245 ic this pathology, Tat was injected into the tail vein of C57BL/6 mice.

246 llow tracking in vivo, and injected into the tail vein of female mice at different ages.

247 assay in which cells were injected into the tail vein of immunodeficient mice.

248 g shRNA against chk was injected i.v. in the tail vein of MDA-MB-231 tumor-bearing female severe comb

249 ted into the circulation through the lateral tail vein of mice, IGF1R disruption also resulted in sig

250 injection of the complexes into the lateral tail vein of mice.

251 t by i.v. administration of a mAb(s) via the tail vein of mice.

252 coccus aureus (MRSA) was inoculated into the tail vein of rats.

253 go in culture and injected into the flank or tail vein of SCID mice, eventual tumor volume and number

254 MBq (104 ng) of radiolabeled antibody in the tail vein of SCID mice, which were then sacrificed at 1,

255 rt here that B16F10 cells, injected into the tail vein of UG-KO mice, form markedly elevated numbers

256 9H11] in the bilayer, were injected into the tail veins of female BALB/c mice bearing right flank EMT

257 Following intravenous injection in the tail veins of homozygous M83 transgenic (M83(+/+)) mice,

258 bitor RNAs against PPP1R1, injected into the tail veins of immune-compromised mice, and followed by n

259 actions were administered intravenously into tail veins of mated BALB/c females at day 0 of pregnancy

260 MV-Edm administered intravenously into the tail veins of mice also showed significant antineoplasti

261 s was injected into the mammary fat pads and tail veins of mice to evaluate tumor growth, and experim

262 Pancreatic cells were injected into the tail veins of mice, and lung metastases were quantified.

263 truct was injected hydrodynamically into the tail veins of mice.

264 Klebsiella pneumoniae was injected into the tail veins of rats and followed with multiple doses of p

265 ific T clone cells were transferred into the tail veins of rats.

266 of 1 x 10(7) T-bodies were injected via the tail vein or directly administered to the subcutaneous t

267 d or 4-fold higher level of hFIX compared to tail vein or intramuscular injections, respectively.

268 MSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately

269 mouse melanoma cells were injected into the tail vein or portal vein of 6-week-old C57BL/6 and nude

270 with SNORA42-siRNA into mice through either tail vein or subcutaneous injection.

271 r injection of vector particles into muscle, tail vein, or portal vein were similar with hFIX detecta

272 14), or 1.0 mg/kg (n = 14) twice weekly via tail vein, or to control groups (n = 13) receiving the v

273 limited relative partitioning to the brain, tail-vein peptide injection revealed tumor targeting in

274 omoter (pCMV-HGF) by rapid injection via the tail vein produced a remarkable level of human HGF prote

275 were injected into the mammary fat pads and tail veins, respectively, of athymic nude mice and asses

276 (WT) littermate control C57BL/6 mice via the tail vein, s.c., and intrasplenic routes.

277 inistered by injection into NOD mice via the tail vein, this FSI formulation significantly suppressed

278 viral genome particles/vector/mouse) via the tail vein to 1-month-old dystrophin-null mice.

279 urine spleen to generate liver metastases or tail vein to generate lung metastases with sequential pr

280 ion probes, as well as sequence controls, by tail vein to immunocompromised female NCr mice bearing h

281 When administered via tail vein to infarcted wild-type male mice, they selecti

282 les were injected into pregnant mice through tail veins to mimic bacteremia, which occurs frequently

283 lactic efficacy in protecting HemA mice from tail vein transection bleeding induced 24-48 hours after

284 30% higher survival relative to rFVIII after tail vein transection inflicted 24 hours after dosing.

285 emic injections of 30 mg/kg MnCl2 H2O in the tail vein using T1-weighted magnetic resonance imaging (

286 V RNA sequences were injected into the mouse tail vein using the hydrodynamics-based transfection pro

287 The injection methods of tail vein v.s.

288 anial melanoma xenografts in SCID mice after tail vein virus application.

289 After injecting mice with rPfHRP2 via the tail vein, we compared analyte levels in both plasma and

290 nous model, bacteria inoculated in the mouse tail vein were observed spreading to multiple tissues.

291 ollected 2 h after mice were injected in the tail vein with (64)Cu-CB-TE2A-LLP2A (5.6-11.1 MBq [150-3

292 Mice were injected via the tail vein with 1.9-3.1 MBq (53-85 microCi) of (124)I-min

293 aring MCF-7 xenografts were injected via the tail vein with 10.5 MBq (283 microCi, 0.235 microg/kg) o

294 er, groups of 3-5 mice were injected via the tail vein with 50 microg of either scVEGF that had been

295 dertaken by injecting male CD-1 mice via the tail vein with 6.03 MBq (163 microCi, 2.55 microg/kg) of

296 nal groups of 3-5 mice were injected via the tail vein with 74-111 MBq of (99m)Tc-scVEGF (or (99m)Tc-

297 termined by injecting male CD-1 mice via the tail vein with either (11)C-BMS-5p 3 or (18)F-FBzBMS 5.

298 SCID-beige mice injected via the tail vein with ERK clones were employed to determine met

299 or in vivo studies, 15 mice were injected by tail vein with increasing levels of an adenoviral vector

300 control proteins and challenged them via the tail vein with S. aureus or other gram-positive or gram-